VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET)...
12 insider purchases on record · latest filing 2025-01-16.
Insiders have also filed 4 sale transactions at VYNE.